Elicera Therapeutics submits Clinical Trial Application to evaluate its CAR T-cell therapy in B-cell lymphoma
Gothenburg, January 26, 2022 - Elicera Therapeutics AB (publ) (“Elicera”), a clinical stage cell and gene therapy company developing next-generation therapies based on CAR T-cells armed with bystander immune activating properties using the company’s commercially available platform iTANK, and oncolytic viruses today announced that it has submitted a Clinical Trial Application (CTA) to the Swedish Medical Products Agency and the Ethics Committee´ to evaluate its CAR T-cell therapy, ELC-301, in treatment of B-cell lymphoma.The study aims to evaluate the safety and efficacy of one dose of CD20